First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 ...Middle East

SHANGHAI, July 8, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the first patient has been dosed in the Phase 1...

Read More Details
Finally We wish PressBee provided you with enough information of ( First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 )

Also on site :

• South Africa seeks US trade deal after Trump’s 30% citrus tariff
• Josh O’Connor Goes Full Cowboy in ‘Rebuilding’ as Director Max Walker-Silverman Takes on Life After the Fires: ‘Loss Often Comes With Love’
• Japan starts deploying Osprey fleet at a new base to beef up southwestern defense